Hepatitis B virus (HBV)is a causative agent for hepatitis, but screening for anti-HBV agents has not been possible because no experimental animals or cell culture systems susceptible to its infection had been available. Recently, this problem was overcome by using transfection to establish a cell line, HB611, that continuously produces HBV-like particles0. When this cell line was used to screen anti-HBV substances, /3-interferon and adenine arabinoside (ara-A), which are clinically used for HBV infection, exhibited anti-HBV activity2).
Oxetanocin A (OXT-A), 9-(2-deoxy-2-hydroxymethyl-/3-D-er^/*r6>-oxetanocyl)adenine, is a novel nucleoside isolated from a filtrate of the Bacillus megaterium culture medium3). This substance was shown to have antiviral activities against herpes simplex virus3) and human immunodeficiency virus4). OXT-A also inhibited HBV DNAreplication in the HB611 cell system50. This paper reports on the anti-HBV activities of derivatives of oxetanocin such as 2-amino-OXT-A, OXT-G, OXT-H and OXT-X, which respectively have 2-amino-adenine, guanine, hypoxanthine, xanthine as the base moiety5). HB611 cells were maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum (General Scientific Laboratories), 100 g/ml of streptomycin, 100IU/ml of benzylpenicillin (Gibco) and 200 jug/ml of geneticin (Gibco) at 37°C in 5% CO2 -95% air. The cells were seeded in 35-mrn CORNING wells at a density of 1 x105 cells/well, using 1.2 ml of the medium. After 2 days of incubation, the mediumwas replaced with the same medium containing the test compound. The cells were incubated for a further 15 days, during which time the mediumcontaining the drug was exchanged every 3 days. The cells were then harvested and cellular DNA was prepared2), and digested with restriction enzyme Hind III (Takara Shuzo Co., Ltd. OXT-A and ara-A, which has been clinically used for viral hepatitis although its effect is incomplete8>9), behaved similarly with respect to the antiviral and cytotoxic activities.
OXT-G and 2-amino-OXT-A showed antiviral effects 12 to 27 times as strong as that of ara-A and were less cytotoxic. Thus, these two compounds are better candidates for anti-HBV drugs. OXT-Hand OXT-Xshowed no potent inhibitory effects on HBVDNAsynthesis, as did acyclovir, a potent anti-herpes simplex virus 645 Table 1 . Anti-HBV activities of oxetanocin derivatives and someother compounds. nd: Antiviral activity was not detected. drug10). Independent of this study, Shimada et al.5), examined the same set of oxetanocin derivatives, and found that OXT-A, OXT-G and 2-amino-OXT-Ashow anti-herpes simplex virus activity.
At present, the mechanism of inhibition of HBV DNA synthesis by OXT-G and 2-amino-OXT-A is not clear, although it is likely that they preferentially affect HBV-related reverse transcriptaseu). Nishikiori, A. Fujii & T. Takita: Derivatives of oxetanocin: Oxetanocins H, X and G, and
